This study is looking into a smartphone app called DailyDose, which is designed to help people with type 1 diabetes manage their condition. The app uses your continuous glucose monitoring (CGM) data and insulin information to give you personalized advice on insulin doses and carbohydrate intake, especially during exercise or when your blood sugar is low. We want to see if using DailyDose can help lower your blood sugar levels, as measured by a blood test called hemoglobin A1c (HbA1c). You might be able to join if you are 18 or older, have had type 1 diabetes for at least a year, can read and understand English, and have an HbA1c between 7.5% and 11.5%. The study is currently recruiting 99 participants, but its overall status is unclear.

Study design

This is an interventional study with a planned enrollment of 99 participants. Participants will be randomly assigned to either use the DailyDose app or be in a control group.

What's involved

You would be in the study for 38 weeks, including a 2-week run-in period. You would receive training on a CGM system and insulin pens, and use an iPhone and Apple Watch provided by the study.

Compensation

Not stated in the trial record.

Follow-up

The main goal of the study is measured at 24 weeks after you are assigned to a group.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.